Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)

Hisashi Hidaka, Namiki Izumi, Takeshi Aramaki, Masafumi Ikeda, Yoshitaka Inaba, Kazuho Imanaka, Takuji Okusaka, Susumu Kanazawa, Shuichi Kaneko, Shinichi Kora, Hiroya Saito, Junji Furuse, Osamu Matsui, Tatsuya Yamashita, Osamu Yokosuka, Satoshi Morita, Hitoshi Arioka, Masatoshi Kudo, Yasuaki Arai